Pharmaceuticals
Breakthrough for medtech pioneer: Syntellix receives product approval for India, opening up fast-growing market with 1.38 billion people
Syntellix CEO Claassen: "Greatest and most important success in the company's history" - Indian CDSCO grants approvals for five MAGNEZIX® product families - The Era of Magnesium for orthopaedics and traumatology now also begins in India - Subcontinent will be the world's most populous growth m...
Cambrex to Invest $30 Million to Expand Manufacturing Center of Excellence at High Point, NC Facility
EAST RUTHERFORD, N.J., Oct. 7, 2021 /PRNewswire/ -- Cambrex today announced that it is expanding its manufacturing center of excellence inHigh Point, NC. The $30+ million investment is designed to meet the continually growing demand for small molecule development and manufacturing services. The ...
Debiopharm and Dexa Medica Launch Triptorelin Collaboration to Bring New Hope to Women With Endometriosis
LAUSANNE, Switzerland and TANGERANG, Indonesia, Oct. 7, 2021 /PRNewswire/ --
Debiopharm (www.debiopharm.com
Luciole Pharmaceuticals and Cyclica Announce Research Collaboration to Accelerate Discovery of Novel Medicines
NATICK, Mass. and TORONTO, Oct. 7, 2021 /PRNewswire/ -- Luciole Pharmaceuticals, a startup company focused on the discovery and development of small molecules that enhance the repair of oxidative damage to mitochondrial DNA (mtDNA), and Cyclica, the partner of choice for data-driven drug discovery...
Kazia Therapeutics to Present at LD Micro Main Event
SYDNEY, Oct. 6, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be presenting at the LD Micro Main Event, to be held virtually and in person from12-14 October 2021. Since...
ArisGlobal LifeSphere® MultiVigilance is selected by Asahi Kasei Pharma
MIAMI and TOKYO, Oct. 6, 2021 /PRNewswire/ -- Asahi Kasei Pharma Corp. has selectedLifeSphere® MultiVigilance as a new safety database with the purpose of building a system that supports efficiency, regulatory compliance, and global collaboration over the long term. In addition, Asahi Kasei Pharm...
Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
ROSCREA, Ireland and FREIBURG, Germany, Oct. 5, 2021 /PRNewswire/ -- Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need gastrointestinal ("GI") disorders, announced today that it has entered into a Licensing and C...
I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting
SHANGHAI and GAITHERSBURG, Md., Oct. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter "ABL"), a South Kor...
RhoVac presents 3-year follow-up results of the phase I/II study in prostate cancer
STOCKHOLM, Oct. 5, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today onOctober 5, 2021, that it has received and validated the top line results from its 3-year follow-up of the patients who took part in its phase I/II study that was concluded in 20...
Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.
MONTREAL, Oct. 5, 2021 /PRNewswire/ -- Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS). Innodem's AI-powere...
NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference
SHELTON, Conn., Oct. 5, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, presented an update of its Pan-Coronavirus COVID-19 Drug Development Program at t...
Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial
SYDNEY, Oct. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced further positive results of data analysis from a phase 1c clinical trial (MF-101) studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis for 28 days at t...
Zuellig Pharma Receives EcoVadis Platinum Medal in 2021 For Sustainability
SINGAPORE, Oct. 5, 2021 /PRNewswire/ -- Zuellig Pharma, a leading healthcare
services provider inAsia, has been awarded the Platinum Medal 2021 by
sustainability ratings specialistEcoVadis
RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
TEL AVIV, Israel and RALEIGH, N.C., Oct. 4, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
Kintor Pharma Announces First Patient Dosing in Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients in US
SUZHOU, China, Oct. 4, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that onOctober 1 its phase III clinical trial of proxalutamide for the ...
Debiopharm Encourages Breakthrough Cancer Research in Japan Through its Competitive JCA Mauvernay Award
LAUSANNE, Switzerland, Oct. 4, 2021 /PRNewswire/ -- Debiopharm (
www.debiopharm.com
Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021
DURHAM, N.C.and BEIJING, Oct. 4, 2021 /PRNewswire/ -- Brii Biosciences
CStone presents ARROW study data for GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer (MTC) for the first time in a late breaking oral abstract session at the 90th Annual Meeting of the American Thyroid Association 2021
* Primary efficacy results showed GAVRETO had robust and durable anti-tumor activity in the Chinese patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC), with a confirmed objective response rate (ORR) of 73.1%. And the 9-month duration of response (DOR) rate was 100% ...
I-Mab Announces Upcoming Participation at October Conferences
SHANGHAI and GAITHERSBURG, Md., Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in October...
Binhai sets ambitious biomedical goals with support of key companies
TIANJIN, China, Sept. 30, 2021 /PRNewswire/ -- A news report by chinadaily.com.cn: The Binhai New Area in North China's port city of Tianjin has gathered together more than 1,500 biomedical companies that have made great scientific achievements in key areas, such as recombinant proteins and stem...
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 315 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 313 media titles]
2026-08-27 10:25AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
[Picked up by 304 media titles]
2026-08-24 10:00Henox and Nexusguard Announce Strategic Alliance at BATIC 2026 to Power and Protect the Next Generation of Digital Infrastructure
[Picked up by 297 media titles]
2026-08-25 10:00OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
[Picked up by 291 media titles]
2026-08-24 15:42